| ID Source | ID |
|---|---|
| PubMed CID | 16193304 |
| CHEMBL ID | 1522572 |
| SCHEMBL ID | 7818408 |
| MeSH ID | M0320633 |
| Synonym |
|---|
| MLS000728904 |
| smr000307182 |
| M-4667 |
| 7-methyltryptamine hydrochloride |
| AKOS001476199 |
| 2-(7-methyl-1h-indol-3-yl)ethanamine hydrochloride |
| FT-0621467 |
| 26346-39-4 |
| 2-(7-methyl-1h-indol-3-yl)ethylamine hydrochloride |
| SCHEMBL7818408 |
| CHEMBL1522572 |
| 3-(2-aminoethyl)-7-methylindole hydrochloride |
| 159730-18-4 |
| mfcd01074518 |
| EN300-7439390 |
| 7-methyltryp-tamine hydrochloride |
| 2-(7-methyl-1h-indol-3-yl)ethanamine;hydrochloride |
| AMY21001 |
| 2-(7-methyl-1h-indol-3-yl)-ethylamine hydrochloride |
| 2-(7-methyl-1h-indol-3-yl)ethylamine hcl |
| 2-(7-methyl-1h-indol-3-yl)ethan-1-amine hydrochloride |
| [2-(7-methyl-1h-indol-3-yl)ethyl]amine hydrochloride |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 100.0000 | AID504339 |
| TDP1 protein | Homo sapiens (human) | Potency | 32.6427 | AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 39.8107 | AID1460 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | AID504332 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 7.9433 | AID624246 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 20.5962 | AID624296 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.0050 | AID1458 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 3.9811 | AID1461 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 10.0000 | AID720709 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inflammation | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |
| Innate Inflammatory Response | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 |